A detailed history of Shell Asset Management CO transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Shell Asset Management CO holds 30,651 shares of NUVB stock, worth $71,723. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,651
Holding current value
$71,723
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Jul 31, 2024

BUY
$1.46 - $3.97 $44,750 - $121,684
30,651 New
30,651 $90,000
Q2 2022

Aug 09, 2022

SELL
$3.24 - $5.85 $19,018 - $34,339
-5,870 Closed
0 $0
Q1 2022

May 04, 2022

SELL
$4.6 - $8.83 $3,983 - $7,646
-866 Reduced 12.86%
5,870 $31,000
Q4 2021

Feb 09, 2022

SELL
$7.75 - $10.05 $806 - $1,045
-104 Reduced 1.52%
6,736 $57,000
Q3 2021

Nov 04, 2021

SELL
$7.78 - $10.0 $1,945 - $2,500
-250 Reduced 3.53%
6,840 $68,000
Q2 2021

Aug 12, 2021

BUY
$9.22 - $14.48 $65,369 - $102,663
7,090 New
7,090 $66,000

Others Institutions Holding NUVB

About Nuvation Bio Inc.


  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $508M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track Shell Asset Management CO Portfolio

Follow Shell Asset Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.